

Reminding your patients to stay safe from the flu

Our objective for this flu season is the same as yours, to help your patients avoid the flu—especially those at higher risk of developing serious flu complications due to an underlying health condition. That’s why Humana supports your care by reminding our members to get their flu shot as soon as it’s available.

The World Health Organization (WHO)¹ recommended and the Food & Drug Administration² approved a 2022–2023 Northern Hemisphere vaccination composition mix for trivalent and quadrivalent influenza vaccines with new antigen strains for A H3N2 and B Victoria. For the third year in a row, the egg-based vaccine preparations will have one set of antigens (unique A H1N1 virus strains), while the cell and recombinant will have another. And while the WHO gave recommendations for both trivalent and quadrivalent formulas, vaccine manufacturers will only be making the quadrivalent versions.³



Egg-based vaccines for 2022–2023; Northern Hemisphere, quadrivalent only

Viral strain

A/Victoria/2570/2019 (H1N1)pdm09-like virus
A/Darwin/9/2021 (H3N2)-like virus
B/Austria/1359417/2021-like virus (B/Victoria lineage)
B/Phuket/3073/2013-like virus (B/Yamagata lineage)

Cell or recombinant-based vaccines for 2022–2023; Northern Hemisphere, quadrivalent only

Viral strain

A/Wisconsin/588/2019 (H1N1)pdm09-like virus
A/Darwin/9/2021 (H3N2)-like virus
B/Austria/1359417/2021-like virus (B/Victoria lineage)
B/Phuket/3073/2013-like virus (B/Yamagata lineage)

There will be two quadrivalent options for seniors (65 and above): Fluzone High-Dose Quadrivalent and Fluvad Quadrivalent. This is the third year where seniors have both options.

The American Academy of Pediatrics advises families to vaccinate their children against influenza with either the flu shot or the nasal spray vaccine (FluMist®) for the best protection against the virus during the 2022–2023 flu season.⁴

In addition to encouraging flu vaccinations for those 6 months and older, the Centers for Disease Control and Prevention notes the following patients are at increased risk of infections and complications:⁵

- Pregnant women
- Children, especially those younger than 2 years old
- People 65 years and older
- People of any age with certain chronic medical conditions, including asthma, diabetes, heart disease and chronic kidney disease
- People of any age who have immunosuppression
- People living in nursing homes and other long-term care facilities



To facilitate correct reimbursement, appropriate administration, vaccine and diagnosis codes are needed for each vaccination claim

- Administration codes for influenza vaccination are 90471, 90472, 90473 and 90474. The Medicare code is G0008. Medicare code G8482 can be used to communicate the vaccination was previously received, possibly elsewhere.
- Vaccine codes can be found below.
- Diagnosis code Z23, encounter for immunization, must be included in any position between 2 and 9.

CPT and HCPCS Influenza Vaccination Codes: 2022–2023

CPT codes	Long description
90662	Influenza virus vaccine (IIV), split virus, preservative-free, enhanced immunogenicity via increased antigen content, for intramuscular use
90672	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use
90674	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative- and antibiotic-free, 0.5 mL dosage, for intramuscular use
90682	Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative- and antibiotic-free, for intramuscular use
90686	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative-free, when administered to individuals 3 years of age and older, for intramuscular use
90688	Influenza virus vaccine, quadrivalent (IIV4), split virus, when administered to individuals 3 years of age and older, for intramuscular use
90694	Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative-free, 0.5 mL dosage, for intramuscular use
90756	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic-free, 0.5 ml dosage, for intramuscular use
HCPCS codes	Long description
Q2035	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Afluria)
Q2036	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Flulaval)
Q2037	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluvirin)
Q2038	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluzone)
Q2039	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (not otherwise specified)

References

1. World Health Organization, last accessed Aug. 5, 2022, www.who.int/news/item/25-02-2022-recommendations-announced-for-influenza-vaccine-composition-for-the-2022-2023-northern-hemisphere-influenza-season.
2. U.S. Food & Drug Administration, last accessed Aug. 5, 2022, www.fda.gov/vaccines-blood-biologics/lot-release/influenza-vaccine-2022-2023-season.
3. Centers for Disease Control and Prevention, last accessed Aug. 5, 2022, www.cdc.gov/flu/prevent/vaxsupply.htm.
4. American Academy of Pediatrics, last accessed Aug. 5, 2022, www.cppdocs.org/blog/aap-flu-vaccine-recommendations/.
5. Centers for Disease Control and Prevention, last accessed Aug. 5, 2022, www.cdc.gov/flu/highrisk/index.htm.



For support, please contact Humana's Provider Call Center (800-448-6262) or your local market representative.